TL;DR
This study reveals that the carbohydrates found in Shenmai Injection (SMI), a traditional Chinese medicine, play a crucial role in improving hematopoietic function during chemotherapy-induced myelosuppression, working synergistically with ginsenosides. This finding challenges the traditional view of TCM components and suggests that simple sugars might be overlooked bioactive agents in complex herbal formulations.
What Problem Does This Paper Address?
Chemotherapy, while effective against cancer, often causes severe myelosuppression, a condition where the bone marrow's ability to produce blood cells is suppressed. This side effect can lead to dose reductions, treatment delays, and increased risk of infection, significantly impacting patient outcomes. Shenmai Injection (SMI), a widely used traditional Chinese medicine (TCM) preparation, is known to alleviate these side effects. However, the specific active components responsible for its hematopoietic benefits, particularly the role of its significant carbohydrate content (fructose, sucrose, maltose), have remained unclear. This paper aims to dissect the contributions of SMI's components, specifically investigating whether these carbohydrates, alongside the well-studied ginsenosides, are essential for its therapeutic effects on myelosuppression.
Methods
The researchers employed a multi-pronged approach to investigate the hematopoietic effects of SMI and its components:
- In Vivo Studies:
- Tumor-Bearing Mouse Model: Mice bearing tumors were treated with 5-fluorouracil (5-FU), a common chemotherapeutic agent known to induce myelosuppression, and then with SMI. This model assessed SMI's ability to mitigate chemotherapy side effects without compromising anti-tumor efficacy.
- Acute Myelosuppression Model: Mice were induced with acute myelosuppression using a high dose of 5-FU. They were then treated with either SMI, a mixture of ginsenosides and carbohydrates (S+Rg), isolated carbohydrates (S), or isolated ginsenosides (Rg). This allowed for the direct comparison of the effects of individual components and their combination.
- Bone Marrow Analysis: Bone marrow nucleated cell (BMNC) counts and colony-forming unit (CFU) assays (for BFU-E and CFU-GM) were performed to quantify hematopoietic recovery. Histopathological analysis of bone marrow was conducted to assess structural improvements.
- Long-Term Bone Marrow Culture: Bone marrow cells from myelosuppressed mice were cultured in vitro to observe the direct effects of SMI and its components on bone marrow stromal cells (BMSCs) and hematopoietic cell proliferation.
- Molecular Analysis:
- RNA Sequencing (RNA-seq): Bone marrow stromal cells (BMSCs) from the acute myelosuppression model were subjected to RNA sequencing to identify differentially expressed genes (DEGs) and understand the molecular pathways affected by SMI, carbohydrates, and ginsenosides.
- Bioinformatics Analysis: KEGG pathway enrichment and Gene Ontology (GO) analyses were performed on the RNA-seq data to identify key biological processes and signaling pathways regulated by the treatments. Network analysis (using STRING and Cytoscape) was used to visualize these molecular interactions.
Datasets
The study utilized:
- Animal Models: Balb/c mice were used for in vivo experiments.
- Cell Lines: CT-26 cells were used to establish the tumor-bearing mouse model.
- RNA-seq Data: Gene expression data from bone marrow stromal cells (BMSCs) of treated and control mice were generated and deposited in the NCBI BioProject database (accession number PRJNA828339).
Key Insights and Ideas
- Carbohydrates as Bioactive Agents: The most significant insight is that the simple carbohydrates (fructose, sucrose, maltose) present in SMI are not merely energy sources but actively contribute to hematopoietic recovery. This challenges the conventional focus on more complex phytochemicals in TCM research.
- Synergistic Action: Both carbohydrates and ginsenosides independently promote hematopoietic function, but their combination appears to be more effective, suggesting a synergistic relationship.
- Distinct Molecular Signatures: While both components influence common pathways like ECM-receptor interaction, Hippo signaling, and Wnt signaling, carbohydrates uniquely regulate genes involved in Glutathione metabolism and B cell receptor signaling. This highlights distinct, yet complementary, mechanisms of action.
- Protective Role in Oxidative Stress: The study suggests that carbohydrates might play a priority role in protecting the bone marrow from oxidative stress induced by chemotherapy, a mechanism that warrants further investigation.
Key Results
- SMI Attenuates Myelotoxicity: SMI treatment improved survival rates in 5-FU-treated tumor-bearing mice and significantly increased bone marrow nucleated cell (BMNC) counts and hematopoietic progenitor cell colonies (BFU-E and CFU-GM).
- Carbohydrates and Ginsenosides Promote Hematopoiesis: In the acute myelosuppression model, both isolated carbohydrates (S) and ginsenosides (Rg) significantly increased BMNC counts. The combination (S+Rg) showed a comparable or slightly better effect than SMI itself.
- Improved Bone Marrow Morphology: Histological analysis revealed that SMI, S+Rg, S, and Rg treatments improved bone marrow structure, reduced hemorrhage, and increased nucleated cell counts compared to the 5-FU-induced model. The combination treatments showed a more pronounced effect.
- Enhanced BMSC Proliferation in vitro: Long-term bone marrow cultures demonstrated that SMI, S+Rg, S, and Rg treatments promoted the proliferation of BMSCs and the formation of hematopoietic cell clusters.
- RNA-seq Reveals Pathway Regulation: RNA-seq analysis identified that carbohydrates, in particular, significantly influenced Glutathione metabolism (e.g., regulating Gstt1, Gstp2, Gsta4, Oplah) and B cell receptor signaling pathways (e.g., Cd19, Cd79a, Cd79b).
Limitations and Future Work
- Dosage and Concentration: The study used a single dosage for SMI and fixed concentrations for the mixtures of ginsenosides and carbohydrates, based on their proportions in SMI. Further investigations are needed to explore dose-response relationships and optimal combinations.
- Mechanism Validation: While RNA-seq identified key pathways and genes, the specific molecular mechanisms of carbohydrates and ginsenosides require further experimental validation.
- Other SMI Components: SMI contains other bioactive compounds, such as ophiopogonins, whose roles in hematopoiesis were not explored in this study. Future work could investigate their contributions and interactions.
- Tumor-Bearing vs. Acute Model: While both models were used, the direct comparison of carbohydrate effects in the context of tumor signaling versus acute myelosuppression could be further elaborated.
The authors suggest that future research should focus on experimentally demonstrating the bioactivity of carbohydrates, alone and in combination with ginsenosides, and exploring the roles of other SMI components.
Summary updated